In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Survival Outcomes Associated with Visualase Ablation of Unresectable Tumors

    Final Number:
    1668

    Authors:
    Jessin Koshy John MD; Adam M Robin BS MS MD; Lisa Scarpace MS; Steven N. Kalkanis MD; Jason M. Schwalb MD , FAANS, FACS; Ian Yu Lee MD

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2015 Annual Meeting

    Introduction: Laser Interstitial Thermal Therapy (LITT) is an emerging, minimally invasive cytoreductive therapy for otherwise unresectable brain tumors. Few studies have addressed survival benefit associated with LITT therapy. This study seeks to determine progression free survival and overall survival associated with laser ablation of otherwise unresectable glioblastomas.

    Methods: Patients undergoing Visualase laser ablation for unresectable glioblastomas were recorded prospectively from 11/15/2013 to 10/17/2014. All patients subsequently received EBRT/temozolamide per Stupp protocol. Follow up data including ablation volume, post-operative change in neurological exam, progression free and overall survival were recorded.

    Results: 7 patients underwent stereotactic biopsy immediately followed by laser ablation. Tumor locations were parietal lobe (3), thalamus (3), and basal ganglia (1). 5 patients received greater than 90% volume ablation of tumor, with a mean ablation volume of 6.38 cm3 and median and mean percentage of ablation of 94.87% and 85.23%, respectively. Change in post-operative neurological exam (new onset weakness and aphasia) was seen in 4 patients, of which all could be attributed to the volume of coverage. These deficits improved in 2 patients. At the present time, 3 patients had progression with a mean progression free survival of 47 days. In addition, 4 patients of the cohort were known to have died with a mean survival of 151 days.

    Conclusions: Given the sensitive location of these tumors, a relatively high number of patients experienced new onset or worsening of neurological deficits, although some patients subsequently improved. Although overall and progression free survival remain low, as is consistent with existing data regarding unresectable glioblastomas, there was a subset of patients who appeared to have longer progression free and overall survivals. Future studies will further characterize these patients to determine the survival benefit conferred by laser ablation.

    Patient Care: This data describing outcomes associated with Laser Interstitial Thermal Therapy (LITT) for ablation of unresectable tumors provides insight as to risks and benefits associated with this new technology.

    Learning Objectives: By the conclusion of the session, participants should be able to describe the implications of utilizing Laser Interstitial Thermal Therapy (LITT) for ablation of otherwise unresectable glioblastomas.

    References: 1. Lacroix, Michel et al. “A Multivariate Analysis of 416 Patients with Glioblastoma Multiforme: Prognosis, Extent of Resection, and Survival.” Collections 112.2 (2009): 190–198. Web. 18 Oct. 2014. 2. Norred, Sarah E., and Jacqueline Anne Johnson. "Magnetic Resonance-Guided Laser Induced Thermal Therapy for Glioblastoma Multiforme: A Review." BioMed research international 2014 (2014). 3. Barrie, M., et al. "Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme." Annals of oncology 16.7 (2005): 1177-1184.

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy